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In the Western population, the incidence of cardiovascular diseases
(CVDs) has increased due to ongoing aging. This represents a health,
economic and social problem mainly due to the dramatic increase in
thenumber of non-autonomous affected individuals. In addition, it is es-
timated that the CVD incidencewill reach 36.9% to 40.5% by 2030, with-
out changes in prevention or treatments [1]. Thus, CVDs are a very
challenge. However, progress has been made in recent years for the
treatments of some CVDs, such as ischemic heart diseases, due to new
thrombolysis and percutaneous coronary intervention procedures [2].
Conversely, for a large CVD group, the management and the outcome
still remain difﬁcult. Typical examples are the aneurysms, and in partic-
ular, sporadic thoracic aortic aneurysms (TAA), whose incidence is in-
creasing in our population, and especially in elderly [3,4]. The etiology
of TAA is heterogeneous and can be classiﬁed in syndromic and non-
syndromic forms. The ﬁrst includes inherited and familiar TAA that
characterize younger patients, the second group includes sporadic or
isolated TAA, that occur in advantage age. Inherited TAAs have an inci-
dence of b5% and are represented by Marfan syndrome, Ehlers-Danlos
syndrome, Loeys-Dietz and aneurysm-osteoarthrosis sindrome. Famil-
ial TAAs have a 20% incidence and are represented by TAA associated
with bicuspid aortic valve, patent ductus arteriosus (PDA) and cerebro-
vascular disease. Isolated or sporadic TAAs have a degenerative etiology
linked to classic cardiovascular risk factors, such as smoking, hyperten-
sion, and hyperlipidemia. Table 1 provides an overview of syndromic
and non-syndromic TAAs, with their corresponding clinical features
[3,4].
The detection of TAA is often fortuitous, occurring during a routine
physical examination or an independent medical evaluation [3,4].
Once suspected, the diagnosis must be conﬁrmed by imaging clinical
modalities (i.e. X-ray,magnetic resonance imaging, computed tomogra-
phy scanning, or ultrasound), which allow the selection of the surgeryTable 1
Clinical features of thoracic aortic aneurysm.
Disorder Main CV features Additional clinical
features
Marfan syndrome Aortic root aneurysm, aortic
dissection, mitral valve
prolapse, main pulmonary
artery dilatation, left
ventricular dysfunction
Lens luxation, pectus
deformity scoliosis, ﬂat
feet, increased arm span
Ehlers-Danlos syndrome Arterial rupture and
dissection, severe valvular
insufﬁciency
Translucent skin,
dystrophic scars, thin lips,
deep set eyes
Loeys-Dietz syndrome Aortic root aneurysm,
aortic dissection, arterial
valve prolapse, congenital
cardiac malformations
Biﬁd uvula/cleft palate,
hypertension scoliosis,
club feet, pectus deformity
Aneurysm-Osteoarthritis
syndrome
Aortic root aneurysm,
aortic dissection, arterial
aneurysms and
dissections, arterial
tortuosity, mitral
valve prolapse, congenital
cardiac malformations
Osteoarthritis, soft skin,
ﬂat feet, scoliosis,
recurrent hernia,
hypertelorism pectus
deformity
Arterial tortuosity
syndrome
Arterial tortuosity, arterial
stenosis and aneurysm
Hyperlax skin and joints
Cutis laxa syndrome Aortic root aneurysm,
arterial tortuosity
Hyperlax skin and joints,
emphysema
Familial thoracic aortic
aneurysm syndrome
Thoracic aortic aneurysm,
dissection
None
Familial thoracic aortic
aneurysm syndrome
with bicuspid aortic
valve
Calciﬁed aortic valve None
Familial thoracic aortic
aneurysm syndrome
with PDA
PDA None
PDA, Patent ductus arteriosus.procedures (including elective surgery or endovascular repair), before
the onset of catastrophic and life-threatening complications (i.e. dissec-
tion or rupture) [3,4]. Furthermore, there are no available biomarkers at
this time for early diagnosis of sporadic TAAs, although emerging evi-
dence points out some of the tissue and serum molecules, which
might play this putative role (see Table 2). On the other hand, sporadic
TAAs have been the object of a very small number of investigations than
familial forms [4]. The molecular and genetics mechanisms of then on-
familial TAA forms (see Table 1), which represent the major number
of cases of TAAs, remain largely unknown [3,4]. As a result, it is difﬁcult
to generalize on disease pathways or genetic risk factors that contribute
to sporadic TAA. In fact, this disease is considered to be a pathology by
unclear mechanisms, and with a very complex clinical presentation,
characterized by the lack of overt symptoms, until dissection or rupture
occur [5,6]. As result, better characterization at the molecular level of
sporadic TAAD is necessary.
We recently summarized, for the ﬁrst time, the very limited litera-
ture data on genetic studies of sporadic TAA in order to identify path-
ways of disease and their genetic variants that modulate its
susceptibility [4]. In Chen, Madonna, Milewicz and colleagues, the role
of genetic predisposition in the genesis of TAAs has been deﬁned, and
in particular it has been shown that loss of smooth muscle α-action
leads to NF-κB-dependent increased susceptibility to Angiotensin II
(Ang II) in smooth muscle cells and aortic enlargement [7]. In addition,
we postulated a pattern of TAA onset, already deﬁned by Ruvolo,
Balistreri and colleagues [8] as double-face signal pathway model, given
its features (see Fig. 4 of Ruvolo et al., 2014 study [8]; http://www.
ncbi.nlm.nih.gov/pmc/articles/PMC4120489/). The model is centered
on an innate immunity receptor signaling pathway of [9], the Toll-like
receptor-4(TLR-4) signaling pathway, which has the role of a hub. TLR-
4 is recognized to have a key function in the host defence against
Gram-negative bacteria, viruses, fungi and mycoplasma [10], but also
in the patho-physiology of several age-related diseases [9,11], including
CVDs, as stressed in our studies [4,8,11,12] and described by other
groups [13–15]. Recently, its role has emerged inmaintaining aortic ho-
meostasis, but also in establishing aorta aneurysm [4,8,16–29].
Based on these observations, in this report we will stress the func-
tional importance of TLR-4 signalingpathwayboth inmaintaining aortic
homeostasis, and evoking aorta aging and disease, such as sporadic TAA,
which will be object of intense description and discussion.
2. Structural and functional features of the aorta in physiological
conditions and during aging
For a better understanding of all the concepts, that will be reported
and discussed, wewill brieﬂy describe the aorta structure and its chang-
es during aging. Subsequently, we will emphasize the molecular and
cellular mechanisms associated with aorta aging.
The aorta is the largest blood vessel in the human body and origi-
nates from the left ventricle of the heart, from which it carries oxygen-
ated blood throughout the body. The aortic size is proportional to the
height and weight of an individual and can be divided into several sec-
tions: ascending aorta, descending aorta and aortic arch, which includes
the thoracic and abdominal aorta (see Fig. 1). The aortic wall consists of
three layers (tunica intima, media and adventitia), which have an ana-
tomical structure similar to that of other vessels, and which play differ-
ent roles in aorta development and homeostasis, and yet in its
pathologic degradation. In particular, the tunica media consists of con-
centric bands of elastin, collagen, and vascular smooth muscle cells
(VSMCs), so called lamellar units. It provides visco-elasticity and it is
the site of degenerative remodeling responsible for aneurysm formation
(see Fig. 2) [30].
Various sections of aorta are also characterized by a different embry-
onic origin. In particular, the aorta section ranging from the ascending
and aortic arch to the arterial ligamentum derives from precursor cells
of the neural crest, while abdominal aortic section arises from
Table 2
Putative tissue and serum biomarkers of thoracic aortic aneurysm.
Name Molecular function Clinical ﬁndings Proposed clinical applications Clinical
implementation
Ref.
Kallistatin Protease inhibitor ↓ in postsurgical sera Postsurgical outcome No [159]
α-2-macroglobulin Acute-phase protein, signaling
molecule
↓ in postsurgical sera Postsurgical outcome No [159]
D-dimer Fibrin fragment ↑dissected TAA Rule out TAA dissection No [160]
hs-TNI Cardiac sarcomeric protein ↑dissected TAA Rule out TAA dissection Yes [160]
TnI Cardiac sarcomeric protein ↑dissected TAA Rule out TAA dissection Yes [161]
NTproBNP Cardiac natriuretic peptide ↑dissected TAA Rule out TAA dissection No [162,163]
RCP Acute-phase protein ↑ in non-surviving patients with
dissected TAA
Prognostic factor of in-hospital mortality after
TAA dissection
No [164]
Hypermethylated
ACTA2
Aortic contractile protein ↑dissected TAA Risk factor of TAA development in the bicuspid
population
No [7,165]
Hypermethylated
PTPN22
T cell receptor signaling ↑dissected TAA Risk factor of TAA development in the bicuspid
population
No [165]
Hypermethylated
TGFβ1
Multifunctional protein that
controls
↑dissected TAA Risk factor of TAA development in general
population
No [165]
TN-C proliferation and differentiation ↑ dissected TAA undergoing
regression
Predictive factor of dissected TAA regression No [166]
IL-6 Extracellular matrix
glycoprotein
↑dissected TAA Risk factor of TAA development in the general
population
No [167]
TNF-α Acute-phase proinﬂammatory
protein
↑dissected TAA Risk factor of TAA development in the general
population
No [168]
TAA, thoracic aortic aneurism; TnI, troponin I; hs-TnI, high sensitive troponin I; NTproBNP,N-terminal pro-brain natriuretic peptide; RCP, reactive C protein; ACTA2, Actin, Alpha 2, Smooth
Muscle, Aorta; PTPN22, Protein Tyrosine Phosphatase, Non-Receptor Type 22; TGF, tumour growth factor; TN-C. Tenascin C; IL-6, interleukin 6; TNFα, tumour necrosis factor alpha.
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that grows through sequential assemblage of lamellar units, reaching
a total of 55–60 units in adulthood. This allows of maintaining a con-
stant ratio between aortic diameter and medial thickness. However,
the thickness of each unit is expanded duringmaturation. The heteroge-
neity of various aortic traits and segmental growth patterns reﬂects the
differences in the density of extracellular matrix (ECM) microﬁbril and
VSMC reactivity to vasoactive growth factors, with downstream effectsFig. 1.Anatomy of the thoracic aorta. Panel A: schematic representation of the thoracic aorta,wh
(3). Panel B: representative two-dimensional echocardiogram image of the thoracic aorta fro
proﬁle of the thoracic aorta from C57 mouse (original images from personal contribution). T
analyzedusing a Vevo 770 equipped with a 40 MHz ultrasonic linear probe (Visual Sonics Inc.,
diameter measurements were made in late diastole.linked to activation of different pathways [4,31], which are different
and able to determine a different susceptibility to the onset of aneurysm
[32].
In addition, the aorta, as well as the entire cardiovascular system
(heart and vascular system) and any other tissue, organ or system, ex-
hibit several age-related changes, both at anatomical and physiological
levels, as clearly demonstrated by Collins and colleagues [30]. Changes
in the aortic structure occur throughout life, but they are mostlyich is divided into several segments: ascending aorta (1); aortic arch (2); descending aorta
m C57 mouse in parasternal long-axis view. Panel C: representative aortic pulse Doppler
wo-dimensional and echocardiography images and doppler signals were recorded and
Toronto, Ontario, Canada). Images were obtained in the parasternal long-axisview. Aortic
Fig. 2. Schematic representation of thoracic aortic aneurysm (TAA) pathophysiology. SMC,
smooth muscle cells; MMPs, metalloproteinases.
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phenotypes are the vascular remodeling (VR) and the medial degener-
ation (MD) (see Fig. 3) [31–40]. Endothelial dysfunction, increased oxi-
dative stress, inﬂammatory reaction, inﬂammatory cell inﬁltration in
the aortic wall, apoptosis of VSMCs, degeneration of aortic media, and
elastin fragmentation and degradation represent their microscopic al-
terations (see Fig. 3) [32–38]. These changes are responsible for the de-
cline in aorta's elasticity [32–38]. As a result, the aorta dilates and
mechanical expansion forces are transferred to ECM elements within
the aortic wall, and in particular to collagen [32–38]. In turn, this causes
collagen remodeling within the tunica media, resulting in a stiffer and
less compliant vessel. Increased aortic stiffness causes increased systolic
and peak pressures, as well as an increase in workload on the heart
[32–38].
Various symptoms and illnesses have been associated with age- re-
lated aortic VR andMD, includinghypertension, atherosclerosis (angina,Fig. 3. Vascular aging and typical aorta aging phenotypes (medial degeneration and vascular
remodeling, which are associated with several changes at microscopical level, including endo
inﬁltration in aorticwall, shortened telomere length, apoptosis of VSMCs, degeneration of aorticarrhythmia, congestive heart failure, coronary artery disease, stenosis,
general ischemia), orthostatic hypotension, aortic aneurysm and dissec-
tion [38]. All these pathologies show an increased incidence in our pop-
ulations and particularly in old people [38].
3. Molecular and cellular mechanisms of aorta aging: the role of
“sterile inﬂammation”
There is a close relationship between aging and CVDs, as recently
pointed byNorth and Sinclair [39]. Aging itself is not a disease. However,
it signiﬁcantly increases the risk of chronic inﬂammatory-related dis-
eases, including CVDs, as outlined above [9,11,and 40]. Themost plausi-
ble relationship is related to the intrinsic characteristics of aging, which
causes many forms of damages at the molecular, cellular, and tissue
level [41]. In turn, this results in a reduced body response and function
[41]. Speciﬁcally, during aging the cells exhibit different abnormalities,
including genomic instability, telomere attrition, epigenetic alterations,
loss of proteostasis, deregulated nutrient sensing, mitochondrial dys-
function, cellular senescence, stem cell exhaustion and modiﬁcation of
intercellular communication leading to cardiovascular dysfunction
(see Fig. 4) [41–43]. This tissue damage causes cell death and chronic in-
ﬂammation, so-called “sterile inﬂammation” (indicating absence of de-
tectable pathogens) or inﬂamm-aging [42,43] through the release of
the so-called senescence associated secretory phenotype (SASP) [44–46].
SASP is represented by a myriad of factors collectively called damage-
associatedmolecular patterns (DAMPs) [40,44–48]. This condition is sup-
ported by “danger theory” introduced by Polly Matzinger [49], based on
the concept that theprimary function of the immune system stays in de-
tecting and protecting the host against danger. Thus, the initiation of the
immune response is not represented by foreign or stranger microbes
(non-self), but by alarm signals generated by injured or damaged cells
and tissues, collectively referred to as DAMPs [46–48].
DAMPs induce sterile inﬂammation through their binding to innate
immune receptors, collectively deﬁned as pathogen recognition recep-
tors (PRRs), including advanced glycosylation end product-speciﬁc re-
ceptor (AGER/RAGE), Toll-like receptors (TLRs), NOD1-like receptors
(NLRs), RIG-I-like receptors (RLRs), and AIM2-like receptors (ALRs)remodeling). Vascular aging determines the onsent of medial degeneration and vascular
thelialdysfunction, increased oxidative stress, inﬂammatory reaction, inﬂammatory cell
media, and elastin fragmentation and degradation, represent theirmicroscopic alterations.
Fig. 4. Intrinsic changes associatedwith vascular aging and cardiovascular dysfunction. Several intrinsic changes, includingmitochondrial dysfunction, telomere attrition and dysfunction,
genome instability and epigenetic alterations, induce severe biological consequences. Precisely, at short-term, cellular senescence of cells of cardiovascular system and exhaustion of stem/
progenitor cells involved in cardiovascular repair, are evocated. As a result of the long-term effects, they, in turn, determine vascular aging and the consequent cardiovascular dysfunction,
responsabile of the development of several CVDs, such as sporadic TAA.
42 C.R. Balistreri et al. / Journal of Molecular and Cellular Cardiology 110 (2017) 38–53[50]. The evocation of sterile inﬂammation causes tissue inﬂammatory/
immune cell inﬁltration, and thus it acts as vicious cycle to further in-
duce tissue and cell damages, and DAMP release. All factors will deter-
mine the onset of age-related diseases [41,43,and 47].
In an attempt to suppressor delay age-associated aorta VR (i.e. aneu-
rysm), VR has been studied in various species including rats, rabbits,
nonhuman primates, and humans, being an evolutionarily conserved
process (see Table 3). The ﬁndings obtained have provided insights
into the molecular and cellular mechanisms of aorta aging in humans
[51–60]. Precisely, it has been shown that age-associated aorta VR is
the result of a sterile inﬂammation, probablymediated by two supposed
mechanisms: 1) inﬁltration of immune cells, that degrade tissues and
release reactive or toxic molecules, causing DAMPs production [61];
2) phenotypic changes in endothelial cells (ECs) and VSMCs evoked
by altered and overload expression of stress and stretch signalingTable 3
A summary of studies on age-associated vascular remodeling.
Studies
(years)
Topic Studied
model
Findin
Wang M. et al. [51] Angiotensin II in age-associated
carotid arterial remodeling
Rats Angio
caroti
Jiang L. et al. [52] Aortic Calpain-1 activity and aging
in vascular smooth muscle cells
Rats Increa
signal
Wang M. et al. [53] MMP 2 and angiotensin II in aging Nonhuman primates Aging
Wang M. et al. [54] Aging of grossly human aortic wall Humans Proin
Wang M. et al. [55] MMP2 and aortic remodeling
during aging
Rats Increa
Wang M. et al. [56] MMP 2 and TGF-beta 1 signaling
within aged arterial wall
Rats MMP
aged
Spinetti G. et al. [57] MCP-1 and CCR2 signaling in
smooth muscle cells during aging
Rats Aortic
musc
Asai K. et al. [58] Vascular endothelial dysfunction
and apoptosis during aging
Monkeys Vascu
athero
Wang M. et al. [59] Proinﬂammatory signaling in
age-associated arterial remodeling
Rats A loca
age-a
Song Y. et al. [60] Expression of proinﬂammatory
mediators in vascular smooth
muscle cells during aging
Mice Aging
in vas
MMP2, metalloproteinase type 2; TGF-beta, tumour growth factor beta; MCP-1, Monocyte chem
ceptor 4.pathways, triggered by different stressors or damage tissue stimuli
throughout life (i.e. hypertension, aging and smoking) [34,36,37,61,
62]. In particular, rennin/AngII, aldosterone/mineral corticoid receptor
(Aldo/MR) and the endothelin-1 (ET-1)/endothelin-1 receptor A (ETA)
signaling system cascades seem to act by inﬂammatory drivers. This ev-
idence is the result of ﬁndings from the Lakatta s' group, using rat
models, [62,63], and Šabovic's group [64], who propose administering
combination of low-dose ﬂuvastatin and valsartan, as anti-aging
drugs. On the other hand, the expression and activity of Ang II, the an-
giotensin converting enzyme (ACE), the Ang II receptor AT1 receptor
within the aorta wall, in particular, in the thickened intima in several
species, including humans, are risen as the age progress [62–71]. Inter-
estingly, also the chymase, another angiotensin-convertase, was found
in the wall of aged aorta [69]. Recently, two additional groups [70,71]
evidenced that Ang II signaling cascades promote aorta remodeling bygs
tensin II activates MMP 2 and mimic age-associated
d arterial remodeling
sed aortic calpain-1 activity mediates age-associated angiotensin II
ing of vascular smooth muscle cells
increases aortic MMP 2 and angiotensin II activity in nonhuman primates.
ﬂammatory proﬁle within the grossly normal aged human aortic wall
sed MMP2 activity and aortic remodeling during aging
2 activate TGF-beta1 and TGF-beta 1-type II receptor signaling in
arterial wall
MCP-1 and its receptor CCR2 increase with age and alter vascular smooth
le cell function
lar endothelial dysfunction was present in oldmonkeys without evidence of
sclerosis, which may be due to endothelial apoptosis and reduced endothelial cell density
l proinﬂammatory signaling loop facilitates adverse
ssociated arterial remodeling
enhances gene and protein expression of IL-6, CCL2 and TLR4
cular smooth muscle cells
otactic protein-1; CCR2, chemokine receptor type 2;IL-6, interleukin 6; TLR4, Toll-like re-
43C.R. Balistreri et al. / Journal of Molecular and Cellular Cardiology 110 (2017) 38–53inducing expression and/or activity of several pro-inﬂammatory tran-
scription factors (located downstream to these pathways). Among
these, ﬁrst is theNuclear factor kappa-light-chain-enhancer of activated
B cells (NF-κB) [41,61,71]. Its activation determines the production and
release of a myriad of factors, including inﬂammatorymediators, mitot-
ic and tropic factors, proteoglycans and metalloproteinase (MMP)s
(especiallyMMP-2 and -9), and vaso-active molecules. Overall, they
constitute the so-called age-associated arterial secretory phenotype
(AAASP) (see Fig. 4 of Ruvolo et al., 2014 study [8]; http://www.ncbi.
nlm.nih.gov/pmc/articles/PMC4120489/) and create a microenviron-
ment, which drives the phenotype shift of both ECs and VSMCs. Thus,
ECs and VSCMs become secretory, migratory, proliferative and senes-
cent, resulting in changes in aorta remodeling. These last include
intimal-medial thickening, ﬁbrosis, calciﬁcation, and aneurysms, associ-
ated with reduction in endothelial-dependent vasodilatation and in-
creased stiffness. Among AAASP components, the main contributors to
aorta aging and remodeling are MMP-9 and -2, which degrade collagen,
elastin, and other ECMmolecules, resulting in increased DAMPs [72,73].
Their relevance in vascular aginghas been conﬁrmedbyMMP inhibition
studies. In particular, Lakatta's group used chronic administration of
broad-spectrum MMP inhibitor, PD166739 in 16-month-old rats for
8 months. The results have shown that effective MMP inhibition delays
age-associated arterial proinﬂammatory signaling, and this is accompa-
nied by the preservation of intact elastin ﬁbers, collagen reduction in,
and the decrease of age-associated increase in blood pressure [74].
Thus, MMP activation plays a central role in aorta age-related remodel-
ing and consequently in pro-inﬂammatory aorta remodeling and stiff-
ening, which are typical pathological entities of several aorta diseases.
These include hypertension, atherosclerosis and aneurysm/dissection,
showing regional speciﬁc onset associated with regional aorta
embryologic origin, regional disease susceptibility and genetic factors
associated with diseases [4,35,75].
4. Toll-like receptor-4 (TLR-4) signaling pathway in aorta homeosta-
sis and health
Previous evidence has shown a key role of TLR-4 signaling pathway
in the onset of myocardial diseases (i.e. septical cardiomyopathy, ische-
mia/reperfusion, heart failure, cardiac hypertrophy and toxic cardiomy-
opathy) [13–15]. In particular, it has been supposed its role of hub in
mediating a tight relationship between induction of chronic inﬂamma-
tion and disease development [9,11]. This is consistent with its expres-
sion not only in immune cells, but also in a wide range of tissue cells,
such as those of the cardiovascular system, and its ability to active im-
mune/inﬂammatory responses by binding exogenous and endogenous
ligands (see their description below) [9,11]. On the other hand, a com-
mon feature of the pathophysiology of a large number of CVDs, includ-
ing myocardial diseases, is the involvement of a robust inﬂammatory
response [9,11]. However, a recent meta-analysis of 15,148 subjects
demonstrated the absence of signiﬁcant associations of the two TLR-4
gene (MIM: 603030) variants [+896A/G (Asp299Gly; rs4986790) and
+1196C/T (Thr399Ile; rs4986791)] with susceptibility to myocardial
diseases, although other studies emphasize strong associations [76]. Ac-
cording to these ﬁndings, our data showed signiﬁcant opposite role of
rs4986790 TLR-4 variant in longevity and myocardial infarction, as
underlined in the study published in 2004 [77] and summarized in
our reviews [9,11,78,79]. In fact, we concluded that the rs4986790TLR-
4 polymorphism,which attenuates receptor signaling, increases the
risk of infections and decreases the risk of atherogenesis, presumably
limiting inﬂammatory responses. Thus, rs4986790 variant could have
a higher probability of longevity in amodern environmentwith reduced
pathogenic load and better control of severe infections by antibiotics
[79].
In fact, the role of TLR-4 mediated receptor signaling pathway in the
context of aorta diseases is also emerging [16–29]. In particular, our
group postulates its fundamental contribution to the development ofsporadic TAA, as reported in the above mentioned model [4,8]. In this
report, wewill discuss these aspectswith particular emphasis, consider-
ing the growing evidence of current investigations. Revealing the role of
TLR-4signaling pathway in sporadic TAA may serve as a starting point
for future studies that lead to a better understanding of the pathophys-
iological basis and perhaps effective treatment of this human disease.
In the following paragraphs, the TLR-4pathwaywill be pointed, in-
cluding the function, expression (the most well-know TLR members),
and itsmodulation induced by genetic variants. In addition, experimen-
tal evidence on the involvement of TLR-4pathway in aorta health and
aorta aneurysms is also described, in particular discussing potential
and hypothetical models on its role in sporadic TAA pathogenesis.
4.1. TLR-4 pathway: structure, ligands, functions, cell expression and mod-
ulation by genetic variants
The TLR-4 pathway, identiﬁed as the ﬁrst human homologue of the
Drosophila Toll [80,81], consists of three domains: an extracellular
leucine-rich repeat (LRR) domain, a trans-membrane domain, and an
intracellular Toll-interleukin-1 receptor (TIR) domain. The extracellular
LRR domain is involved in the recognition of the lipopolysaccharide
(LPS) of Gram-negative bacteria, the prototypic TLR-4 ligand or speciﬁc
Pathogen Associated Molecular Patterns (PAMPs). Other exogenous
TLR-4 PAMPs are the fusion protein of respiratory syncytial virus, the
envelope protein of mousemammary tumour virus, and others as sum-
marized in a recent review from Mukherjee and colleagues [10]. Fur-
thermore, endogenous molecules produced by cell and tissue damage,
DAMPs, can interact directly or indirectly with the TLR-4 pathway,
such as heat-shock proteins (HSPs), hyaluronic acid, β-defensin-2,
oxidized-LDL (ox-LDL), ﬁbronectin, heparin sulfate and ﬁbrinogen,
and amyloid peptide and others [47]. Its activation involves a down-
stream signaling mediated by several intracellular adaptor molecules,
inducing the activation of various transcription factors, such as NF-kB,
and consequently the release of several inﬂammatory mediators [11].
TheTLR-4 pathway also triggers the instructive immunity. In antigen-
presenting cells, TLR-4 pathway activation induces the expression of co-
stimulatory molecules and the Major histo-compatibility complex class
II antigens, which help to support the activation of instructive responses
[11]. TLR-4 is actually expressed on several immune cells, including clas-
sic antigen-presenting cells (dendritic cells, monocyte-macrophage
cells), as well as B and T cells. These data conﬁrm the capacity of these
receptors to link innate and instructive immunity [11]. Different types
of tissue cells can also respond to inﬂammatory stimuli through TLR-4,
which is also expressed in epithelial cells at potential sites of pathogen
entry, including skin, respiratory, intestinal and genitourinary tracts,
and on EC and VSMC cells, but also in other tissue cells [11].
The activity and function of TLR-4 seem to be modulated by genetic
variations, mainly by single nucleotide polymorphisms (SNPs). The
gene sequencing (MIM: 603030; mapping in human beings in the
9q32-q33 region) of severalmammals has identiﬁed several genetic var-
iantsmainly in the LRR domain [11]. This suggests a high conservation of
innate pathways among organisms that involves the TIR domain. In any
case, this concept seems to be in line with the ﬁnding that the innate im-
mune system shows a high degree of homology in different organisms,
including mammals, insects, and plants, and apparently it has been
strongly preserved during evolution [11]. Accordingly, the strong varia-
tion of the LRR region, involved in the recognition of PAMPs (or
DAMPs), is probably the result of evolutionary pressure induced by
host's pathogens [11]. In addition, most of these variants are in the
third exon, that encodes the LRR region, and they have a low frequency
in human populations (b1%) [11]. On the other hand, in humans a higher
frequency (N5%) has been evidenced for only two SNPs, +896A/G
(Asp299Gly; rs4986790) and +1196C/T (Thr399Ile; rs4986791)
(above mentioned). The two SNPs, as ﬁrst suggested by Arbour and col-
leagues [82], induce a blunted response to LPS. In addition, it has been
described that the two SNPs exist in a co-segregated (Asp299Gly/
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haplotypes, referred to as wt/wt, Asp299Gly/wt, Thr399Ile/wt, and
Asp299Gly/Thr399Ile [82]. They are differently represented in the
world population with a speciﬁc geographic distribution. This might be
the result of differences in environmental pathogenic pressure [83,84]
in the human population during the migration into Europe, Asia, and
the NewWorld [85,86]. In addition, these TLR-4 haplotypes are pheno-
typically associated with changes in the production of cytokines, mainly
those carrying the Asp299Gly mutation [83–86]. In particular, the
Asp299Gly/Thr399Ile haplotype seems to induce a phenotypic effect
characterized by reduced production of pro-inﬂammatory cytokines
[85,86]. On the other hand, conﬂicting data have emerged on the pheno-
typic effect of the four TLR-4 haplotypes. Discordant results also exist in
the literature on the role of the two TLR-4 SNPs not only for the risk of
myocardial diseases (as above described), but also for other age-related
diseases, such as Alzheimer diseases, prostate cancer, and longevity, as
also described in our studies [9,11,76–79].
4.2. Experimental evidence on the involvement of TLR-4 in aorta health and
disease
As above reported, the TLR-4 signaling pathway is also expressed in
EC and VSMC cells. As a result, in 2008 Pryshchep and her group [87] ex-
amined the expression proﬁle of TLRs from 1 to −9 in six different
human macrovessels (temporal, carotid, subclavian, mesenteric, iliac,
and thoracic aorta) collected during postmortem examinations of 37
donors (mean age 64 years; 25males, 12 females; dead for causes unre-
lated to aortic disease andwithout sepsis at death time, as conﬁrmed by
autopsy), by using quantitative-RT-PCR and immuno-histochemistry
with primary antibodies (CD11c, TLR2, TLR-4, TLR5, CD86). Their results
demonstrated that the TLR expression levelswere signiﬁcantly different
(p b 0.001), by comparing the 6 vascular territories. In particular, the
data obtained demonstrated a ubiquitous and abundant expression of
TLR-4 among the 6 macro-vessels, compared to the other TLRs. Howev-
er, higher TLR-4 levels were detected in the three aorta laminae. This
heterogeneity has led Pryshchep and her groupto suggest the existence
of a functional specialization in the artery surveillance, with each vascu-
lar lamina region dedicated to a selected spectrum of TLR-4 ligands. In
addition, they propose that this specialization of blood vessel territories
may reﬂect the stringent target tissue tropism of target tissue of inﬂam-
matory vasculopathies [87].
In a speciﬁc aortic case, these data suggest that the TLR-4 pathway
can play a key role in mediating physiological aortic homeostasis, by
providing protection against pathogens and DAMPs, as well as in
contributing to several pathological aorta phenotypes, including
hypertension, MD, VR and atherosclerosis. These latter appear to have
an onset in speciﬁc aortic regions. Today, the concept of a regional het-
erogeneity of aorta diseases, such as thoracic and abdominal aneurysms,
is emerging [4,35,and 36].
4.3. The role of TLR-4 in the maintenance of aorta homeostasis
The role of TLR-4 in aortic health (see Fig. 5) and the disease has re-
cently emerged. A recent survey reported the involvement of the TLR-4-
mediated signaling pathway in the maintaining the integrity and nor-
mal turnover of endothelium. Speciﬁcally, He and colleagues analyzed
human umbilical vein-derived endothelial progenitor cells (EPCs) and
demonstrated that TLR-4 is expressed in these cells and it is involved
in inducing proliferation and maintaining EPC stemness, probably
through a cross-talk with other evolutionally conserved pathways,
such as Notch pathway [88,89]. This interplay could allow a normal
re-endothelialization and neovascularization, an increase in EPCs levelsFig. 5. A–C. TLR4 signaling pathway in homeostasis and sporadic TAA. In A, it describes a homeo
with other pathways (see text). In B, it describes how high levels of DAMPs determine a sustai
hypoxia, Notch, NO, MMP, NF-Kβ pathways. As a result, endothelium dysfunction, hypertension, min peripheral circulation, improving prognosis of aorta/cardiovascular
diseases. Consequently, Li and colleagues [90], by investigating the
EPC function in GroEL1 (a heat shock protein 60 of Chlamydia pneumo-
nia)-administered EPCs in hind limb-ischemia inC57BL/B6 and C57BL/
10ScNJ (a toll-like receptor 4 (TLR-4)mutation)mice and humans, pro-
vided with relevant evidence. Precisely, they observed that GroEL1 im-
paired the capillary density recovery, probably by TLR-4 in mice,
including EPC mobilization and vessel formation as well as endothelial
NO synthase (eNOS) expression in ischemic tissue. Additionally, the
GroEL1 administration also impaired the migration and vasculogenesis
of late EPCs in vitro and induced EPC senescence by activation of
caspases, p38MAPK and ERK1/2. Furthermore, it also decreased the ex-
pression of integrin α1,−α2,−β1,−β3and E-selectin, but it induced
inﬂammatory responses in EPCs. These ﬁndings propose that TLR-4
and impaired NO-related mechanisms could contribute to the reduced
number and functional activity of EPCs in the presence of
C. pneumonia GroEL1and favor atherosclerosis onset [90]. Therefore,
they suggest the relevance of this pathway in the protection against in-
fective agents and in the maintenance of a favorable endothelial micro-
environment for the physiological aortic function.
Another recent study performed by Bucci and colleagues in 2013
[91] reported that TLR-4 contributes to vascular homeostasis through
a cross-talk with another signaling pathway, the Proteinase-activated
receptor-2 (PAR-2). Speciﬁcally, they used thoracic aortas from both
naïve and endotoxaemic rats for in vitro studies, and from TLR-4(−/−
) mice. PAR-2 expression, but not TLR-4, was increased in the aortas
from endotoxaemic rats. PAR-2 AP-induced vascular relaxation was in-
creased in aortic rings of LPS-treated rats. TLR-4 inhibitors, curcumin
and resveratrol, reduced PAR-2 AP-induced vascular relaxation and
PAR-2 AP-induced hypotension in both naïve and endotoxaemic rats.
Moreover, in TLR-4(−/−) aortic rings, expression of PAR-2 was re-
duced, and vasodilatation- induced by PAR-2 APwas impaired, with re-
spect to wild-type mice, and yet after treatment with resveratrol and
curcumine. Thus, they concluded that a cross-talk between PAR-2 and
TLR-4 contributes to vascular homeostasis, creating a network with
other stress and stretch pathways, including ACE, eNOs, andMMP path-
ways, [91] as demonstrated also in our model [8].
Overall, these data suggest that aorta homeostasis is the result of a
very complex signaling network (see Fig. 5) between the TLR-4 signal-
ing receptor itself pathway and other inﬂammatory and non-
inﬂammatory pathways, some of which have been mentioned above,
such as Notch pathway [89]. The growing evidence is also including
other pathways, such as transforming growth factor-β (TGF-β) [92]
and hypoxia pathways [93]. Among them, the Notch pathway (consti-
tuted by Notch receptors 1, 2, 3, and 4 and Delta-like ligands 1, 4 and
Jagged 1, 2 ligands), an evolutionarily conserved pathway, has attracted
the attention of researchers in the cardiovascular ﬁeld [89]. The Notch
pathway is fundamental to the development of all tissues, organs and
systems of human body, as well as cardiovascular system, including
aorta [94–97]. In aorta, Notch pathway is involved in the development
of various aortic sections, and it appear to mediate the maturation of
precursor cells from neural crests, and especially the differentiation of
VSCMs [89,97,98]. However, in post-natal vasculature, Notch receptors
1, 2, 3, and 4 and Delta-like ligands 1, 4 and Jagged 1, 2 ligands are
expressed in both ECs and VSMCs [89,97,98]. Precisely, Notch1
and Notch4 are predominant in aortic ECs and Notch3 in aortic VSMCs
[89,98]. However, their complex and multiple roles, ranging from
angiogenesis regulation, aorta homeostasis, to pathological conditions
including inﬂammation, atherosclerosis, aorta diseases associated with
the onset of both MD and VR, are still unclear. However, a close cross-
talk with TLR-4 pathway has been proposed, which seems to justify its
multitude of actions, and co-temporally contributes to the variousstasis condition determined by a short activation of this pathway, followed by a cross-talk
ned excessive activation of TLR4 signaling pathways, followed by a cross-talk with TGF-β,
edial degeneration, vascular remodeling and sporadic TAA are induced (see panel C).
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aorta [89]. Current evidence supports this. For example, Zeng and col-
leagues showed that Notch-1 mediates the pro-osteogenic response to
TLR-4 stimulation in human aortic valve interstitial cells (AVICs) [94].
Thus, they concluded that this pathway could be a potential therapeutic
target for prevention of progression of calciﬁc aortic valve disease
(CAVD) [94]. In another study performed in 2014 [95], the same group
tested the hypothesis that oxidized low-density lipoprotein (oxLDL)
increases the osteogenic responses in human AVICs, by modulating
the TLR-4-NF-κB pathway and Notch1 activation. AVICs were isolated
from normal human aortic valves and treated with LPS (0.1 μg/ml),
oxLDL (20 μg/ml) or LPS plus oxLDL for 48 h. The results obtained
demonstrated that oxLDL up-regulated the bone morphogenetic
protein-2 expression in humanAVICs and synergizedwith LPS to induce
high AVIC osteogenic responses. Hence, the authors have shown that
oxLDL exert their effect through modulation of the Notch1-TLR-4-NF-
κB signaling cascade [95]. Moreover, Kerr and colleagues demonstrated
in mice that the stability and function of adult vasculature is supported
by Akt (a kinase protein representing a TLR-4-signaling adaptor [99])/
Jagged1 signaling axis in endothelium [100].
This cross-talk between TLR-4 and Notch pathways (highlighted in
other age-related diseases, as is largely underlined in our recent review
of the Notch pathway [89], andwith other abovementioned pathways)
supports both the versatility of action and function of TLR-4 itself path-
way to induce several cellular responses, and pleiotropic effects in the
aorta (and speciﬁcally in the various aortic sections). These last reﬂect
not only thecomplexity and the fundamental features of this pathway
(as stressed above), but also its ability to be modulated and regulated
by genetic variants (as reported above), but also by intrinsic down-
stream pathways and extrinsic molecules. To date, several regulators
have been identiﬁed. They are involved in inhibiting an over- or unnec-
essary activation of TLR-4 pathway, as well as other PRRs. In Table 4,
many of these molecules are listed and described [101–104].
In addition, the recent research points thatmiRNAs (i.e. miR21,miR-
let7, miR146a, miR-155, and miR-126) could play important roles in
modulating gene expression of TLR-4 pathway in the aortic wall and
proteinic levels. miRNAs seem to have dual roles: a) the activation of
TLR-4-mediated pathway activation and b) the inhibition of NF-κB
signaling, in a complex scenario where low and chronic inﬂammation
prevails, and probably also sustained by cell senescence secretome.
miRNAs inhibition effect probably belongs to the various levels of
anti-inﬂammatory pathways that have evolved to lower the TLR-4
signaling pathway to prevent cell and aortic destruction [105–107].
In the complex, all these data reveal an emerging aspect of TLR-4 sig-
naling pathway that is its involvement in aortic physiology. This may
suggest newprospects for theuse of TLR-4-relatedmechanisms tomod-
ulate the EPCs production for clinical use [34].Co-temporally, they point
that TLR-4 signaling pathway has a multi-faceted biology and complex
function, able to mediate not only protective biological effects for
aorta health, but also dangerous biological functions, including the
onset of aortic diseases (for this reason we have deﬁned the TLR4 path-
way as the signaling pathway from the double-face, see above) [8].
5. Role of TLR-4 pathway in aneurysms (sporadic TAA)?
Agrowingnumber of studies report promising data on the role of TLR-
4 signaling pathway in human aortic diseases, such as aneurysms (see
Fig. 5B and C). The ﬁrst evidence derives from data on the cellular expres-
sion and involvement of the TLR-4 signaling pathway in atherosclerotic
arteries, and precisely on ECs, macrophages [108,109] and adventitial ﬁ-
broblasts of these arteries [110]. In 2004, the group of De Kleijn [111],
using a femoral artery cuff model in the atherosclerotic ApoE3 (Leiden)
transgenic mouse and inducing plaque formation through LPS-mediated
TLR-4 activation, demonstrated that the TLR-4 signaling pathway is in-
volved in outward arterial remodeling, probably through up-regulation
of TLR-4 itself and its ligands. In 2006, Lin and colleagues [112], by usingcell cultures of human aortic smoothmuscle cells (HASMCs) from vessels
obtained from Zeal and white rabbits treated or without intravenous
injections of LPS (110 ng/kg), evidenced that the stimulation of
HASMCs with LPS signiﬁcantly increased the TLR-4 expression. In-
creased TLR-4 expression was observed to be controlled by NADPH
oxidase activation, mRNA stabilization, and MAPK signaling path-
ways. As a result, this promoted a HASMCs inﬂammatory phenotype
and vascular remodeling [112]. In addition, in 2007, Schultz and col-
leagues [113], using human VSMCs cell cultures derived from diges-
tion of human coronary artery or pulmonary artery, detected that
autocrine actions of endogenous interleukin (IL)-1 α, mediated at
least in part via IL-1RI signaling, contributed to a pro-proliferative
and proinﬂammatory phenotypic shift in TLR-4-activated human
VSMCs. As a consequence, they suggested a pathogenic role of TLR-
4 pathway in vascular disorders. Based on this evidence, Pi and col-
leagues [114] recently investigated the essential role of reactive ox-
ygen species (ROS) in inducing vascular TLR-4 expression and
neointimal formation. Precisely, they tested the hypothesis that
ROS promote VSMC proliferation and migration by enhancing TLR-
4-mediated inﬂammation, and ultimately leading to intimal hyper-
plasia after injury. Reciprocally, inhibition of ROS generation might
restrain this progress. As a result, male TLR-4-deﬁcient mice
(C57BL/6 J background) and wild-type mice (WT, C57BL/6 J) at
8–10 weeks of age were used to obtain VSMCs from thoracic aorta.
The generation of ROS was pharmacologically manipulated respec-
tively by Platelet-derived growth factor (PDGF)-BB and apocynin, re-
spectively. They observed that VSMCs from thoracic aorta exposed to
PDGF-BB showed signiﬁcant increase in the generation of ROS, which
was effectively suppressed by apocynin. Inhibition of ROS attenuated
both TLR-4 and the expression of proinﬂammatory cytokines in
VSMCs, and was accompanied by a signiﬁcant inhibition of VSMC
proliferation and migration, and neointimal formation. Thus, they
provided evidence that ROS may be a key trigger in evocating both
TLR-4-mediated vascular inﬂammation and intimal hyperplasia.
Cotemporally, they suggested that the inhibition of the primary
source of ROS could mitigate the TLR-4-mediated proinﬂammatory
and proliferative phenotype of VSMCs, and reduce the detrimental
arterial remodeling and inﬂammatory reaction (i.e. that observed
in the early stages of atherosclerosis) [114]. In addition, in 2012 the
group of Garcia-Rodrigues [115] investigated TLR-mediated inﬂam-
mation and osteogenesis in interstitial human cells, isolated from
stenotic and non-stenotic aortic valves and stimulated with viral
and Gram-negative bacteria molecular patterns. TLR- expression
and signaling were evaluated by several assays, including
quantitative-PCR and ﬂow cytometry, to Western blot analysis,
ELISA, and cytokine arrays. Osteogenesis was detected by determin-
ing alkaline phosphatase activity. The results obtained demonstrated
that interstitial cells from control valves expressed high levels of TLR
mRNA, and precisely they showed higher levels of TLR-4 pathway
mRNA. In contrast, the cells from stenotic valves had higherTLR-4 and
TLR2 and lower TLR5 and TLR9 transcript levels. Furthermore, analysing
the pro-inﬂammatory pathways, they also detected thatTLR-4, TLR2 and
TLR3 ligands induced an early activation of NF-κB and p38 MAPK in the
cells from control and stenotic valves. Remarkably, when TLR sensing
viral patterns were studied, they also assessed a sustained TLR3-
mediated activation of NF-κB, a κB independent induction of catalytically
active cyclooxigenase (COX)-2 and ICAM expression, and induction of a
lot of chemokines. Moreover, they showed that TLR3 and TLR-4 agonists
induced alkaline phosphatase expression and activity. Thus, they conclud-
ed that exposure of aortic valve interstitial cells to viral and Gram-
negative bacteria molecular patterns induces distinct and long-term
TLR-mediatedpro-inﬂammatory andpro-osteogenic responses, likely rel-
evant in the pathogenesis of degenerative aortic stenosis [115].
These encouraging data have led several research groups to examine
the role of TLR-4 signaling pathway in aorta aging, and in vascular path-
ological conditions that is VR and MD, signiﬁcantly associated with the
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the inﬂammatory response of aortas from young (2–4 months) and
aged (16–18 months) mice under no stimulatory conditions. TheyTable 4
Intrinsic and extrinsic or exogenous regulators of TLR-4 pathway [101–104].
Regulators Type
sMyD88 Intrinsic molecule
Toll-interacting protein (Tollip) Intrinsic molecule able to interac
of the TIR superfamily, including
A20 Intrinsic molecule, initially ident
zinc-ﬁnger protein A20 expressio
both TLR4 ligands, LPS and TNF,
cell types, which suggests that it
TLR function
Silenced suppressor of cytokine signaling 1 (SOCS1) Intrinsic molecule involved in ne
cytokines that signal through the
TRIF-related adaptor molecule (TRAM) Intrinsic molecule involved in mu
including TLR-4 signaling cascad
Sterile alpha- and armadillo-motif-containing protein
(SARM)
Intrinsic molecule: another TIR d
protein
Interferon (IFN) regulatory factor (IRF) 4 Intrinsic molecule involved in th
TLR-inducible genes
A tumour necrosis factor, alpha-induced protein 8
(TNFAIP8), TNFAIP8-like 2
Intrinsic molecule associated wit
cascades, including TLR-4 signali
Nucleotide binding oligomerization domain
(NOD)-like receptor (NLR) family member ×1
(NLRX1)
Intrinsic molecule involved in in
Post-translational modiﬁcations such as
phosphorylation and ubiquitination
Intrinsic mechanisms
The orphan nuclear receptor, small heterodimer
partner (SHP, also known as NR0B2
Intrinsic molecule
Mitogen and stress activated protein kinase (MSK) 1
and 2 activated in the mitogen-activated protein
kinase (MAPK) cascade
Intrinsic molecules involved in m
cascades, including TLR-4 signali
TGF-b-activated kinase 1 (TAK1) Intrinsic molecules involved in m
cascades, including TLR-4 signali
Several phosphatases and deubiquitination enzymes
(DUBs)
Intrinsic molecules involved in T
DUBA (deubiquitinating enzyme A) Intrinsic molecules involved in T
Viral and bacterial Proteins (including Hepatitis C virus
(HCV) protein NS3-4A; Vaccinia virus (VACV)
protein A46R; IpaH9.8 protein from Shigellaﬂexneri;
Mycobacterium tuberculosis wall component)
Exogenous molecules
Soluble TLR4 molecules Extrinsic molecules
TAM receptors Extrinsic moleculesobserved increased IL-6 basal levels in aged aortas. In addition, aged aor-
tic VSMCs showed ahigher basal release of IL-6 than youngVSMCs. Using
gene and protein expression analysis, they also showed that aged VSMCsAction
The short form of MyD88 (sMyD88) substitutes MyD88
but cannot send signals downstream
t with several members
TLR2 and TLR4
Tollip interacts with IRAK to decrease phosphorylation
iﬁed as a TNF-induced
n is rapidly induced by
and is expressed in many
is involved in regulating
A20 deubiquitylates TRAF6
gative regulation of
JAK/STAT3 pathway
SOCS1 regulates phosphoryltation of IκBα, p38, and JNK
ltiple signaling cascades,
e
TRAM adaptor with GOLD domain (TAG), identiﬁed as a
variant of TRAM, competes with TRAM for
TIR-domain-containing adaptor protein-inducing IFN-β
(TRIF) binding and inhibits the dependent pathway. TAG
localizes to the late endosomes and is required for TLR4
degradation after lipopolysaccharide (LPS) treatment,
indicating that TAG may mediate destabilization of TLR4
by delivery to lysosomes, as well as inhibiting TRIF
binding
omain containing SARM can block TRIF complex formation by directly
binding to TRIF after LPS treatment
e induction of a set of IRF5 directly interacts with MyD88 to induce a set of
TLR-inducible genes. IRF4 is induced by TLR activation
and competes with IRF5 for binding to MyD88, resulting
in shutdown of IRF5-dependent gene induction. IRF4-
deﬁcient mice are hypersensitive to DNA-induced shock
accompanied by increased cytokine production
h multiple signaling
ng cascade
It binds to caspase 8 and regulates activator protein
(AP)-1 and NF-kB activation
ﬂammasome activation NLRX1 undergoes K63-linked polyubiquitination after LPS
treatment and dissociates from TRAF6, resulting in
binding to the activated kinase domain of IKKb via the
leucine-rich repeat(LRR) domain
Post-translational modiﬁcations such as phosphorylation
and ubiquitination also play important roles in signal
transduction by regulating interactions among adaptor
proteins.
SHP (also known as NR0B2) has been identiﬁed as a
negative regulator of TLR signaling by inhibiting TRAF6
ubiquitination. Precisely, It has also been demonstrated
that TLR-4 stimulation induces SHP expression through
AMP-activated protein kinase (AMPK)
activation-dependent intracellular Ca2+ inﬂux mediated
by TLR-4
ultiple signaling
ng cascade
MSK1 and MSK2 limit the proinﬂammatory effects of
TLR4 signaling MSK1 and MSK2 induce the binding of
phosphorylated transcription factors cAMP responsive
element binding protein 1 (CREB) and activating
transcription factor 1 (ATF1) to the promoters of the
anti-inﬂammatory cytokine IL-10
ultiple signaling
ng cascade
TAK1 negatively controls p38 activation in myeloid cells
(neutrophils and macrophages)
LR-4 signaling cascade The Src homology 2 domain-containing protein tyrosine
phosphatase-1 and−2 (SHP-1,−2) are involved in TLR
signaling. SHP-1 suppresses IRAK1 and IRAK2 activities,
resulting in decreased production of proinﬂammatory
cytokines and increased production of type I IFN. SHP-2
negatively regulates TRIF-dependent type I IFN
production
LR-4 signaling cascade DUBA has been identiﬁed as a negative regulator of type I
IFN production
They induce inhibition of TLR-4 signaling cascade
They act as decoy receptors inhibiting TLR-4 signaling
pathway
TAM receptors are involved in the inhibition evocating
the expression of regulator downstream molecules of
TLR-4 cascades
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(e.g., intracellular adhesion molecule 1), and mainly of TLR-4 pathway.
The group of Eissler and colleagues [117] also evidenced that age-
related hypertension is able to induce vascular inﬂammation via TLR-4
expression. This evidence has recently been conﬁrmed by other groups.
In 2014, McCarthy and colleagues [118], established that DAMPs, re-
leased by damaged tissues and entered in circulation, activate TLRs,
and in particular the TLR-4 pathway, in vascular somatic cells of the,
and consequently induce inﬂammation, vasoreactivity, and vascular re-
modelingwhich result in hypertension. Thiswas understoodby Sollinger
and colleagues [119], using TLR-4(−/−) and wild-type mice. De Batista
and colleagues [120] reported a key role of AngII in contributing to TLR-4
up-regulation, VR and hypertension in aortas from Wistar rats treated
with a non-speciﬁc IgG (1 μg/day) and adultsmale ratswith spontaneous
hypertensive (SHRs) treated with losartan (15mg/kg·day), non-speciﬁc
IgG or neutralizing antibody anti-TLR-4 (1 μg/day). In particular, they
have shown that SHR treatment with the anti-TLR-4 antibody reduced
blood pressure, heart rate and phenylephrine-induced contraction,
while improved the impaired acetylcholine-induced relaxation. Further-
more, it increased the phenylephrine contraction after endothelium re-
moval and abolished the inhibitory effects of apocynin and catalane on
the phenylephrine-induced response, as well as its enhancing effect of
acetylcholine-induced relaxation. In SHR VSMCs, AngII increased TLR-4
mRNA levels, while losartan reverted them. Moreover, the use of CLI-
095, a TLR-4 inhibitor, mitigated the increases in NAD (P) H oxidase ac-
tivity, superoxide anion production,migration and proliferation, induced
by AngII. Thus, the Batista's group concluded that the TLR-4 pathway ac-
tivation due to increased RAS activity is involved in hypertension, and
this pathway contributes to the endothelial dysfunction associated
with this pathology, by inducing oxidative stress [120]. These ﬁndings
were validated in 2015 by Hernanz‘s group [121]. Precisely, they exam-
ined whether TLR-4 activation likely contributed to Ang-II-induced-
hypertension and the related vascular structural, mechanical and func-
tional alterations. For this purpose, AngII was infused (1.44 mg kg−1
day−1, s.c.) for 2 weeks in C57BL6 mice, treated with a neutralizing
anti-TLR-4 antibody or IgG (1 μg day−1). The values of systolic blood
pressure (SBP) and the levels of aortic cytokines were measured. The
structural, mechanical and contractile properties of aortic andmesenter-
ic arterial segments have been measured by myography and histology.
RT-PCR andWestern blotting were also used to evaluate tissues and cul-
tured VSMCs from hypertensive rats (SHR). The ﬁndings obtained dem-
onstrated that aortic TLR-4 mRNA levels were elevated after AngII
infusion. In contrast, the administration of anti-TLR-4 antibody to
AngII-treated mice reported them to physiological values, but it in-
creased SBP and TNF-α, IL-6 and CCL2 levels. In addition, it resulted in
vascular and structural changes, with altered aortic phenylephrine and
Ach induced responses and increased NOX-1 mRNA levels, superoxide
anion production and NAD(P)H oxidase activity and the effects of cata-
lase, apocynin on vascular responses. Furthermore, it reduced the NO re-
lease and effects of L-NAME on phenylephrine-induced contraction. In
VSMCs, theMyD88 inhibitor ST-2825 reducedNAD (P)Hoxidase activity
induced byAngII. The TLR-4 inhibitor CLI-095 reduced the increase of ex-
pression of phospho-JNK1/2 and p65 NF-κB subunit nuclear protein in-
duced by AngII. These relevant results have suggested that TLR-4 up-
regulation associated with both hypertension and evocation of mecha-
nisms involving oxidative stress is likely able to contribute to several
pathological conditions, including inﬂammation, endothelial dysfunc-
tion, vascular remodeling and stiffness. For validating these data, in
2015 Bomﬁm and colleagues [122] treated SHR and Wistar rats with
anti-TLR-4 antibody (1 μg/day) or unspeciﬁc IgG for 15 days (i.p.).
Anti-TLR-4 treatment resulted in the production of ROS and IL-6 expres-
sion in mesenteric resistance arteries from SHR, when compared with
IgG-treated SHR. Furthermore, the anti-TLR-4 treatment also abolished
the increased vascular responsiveness to noradrenalin in IgG-treated
SHR, and the inhibition of NFκB decreased noradrenalin responses only
in IgG-treated SHR. Mesenteric arteries from SHR treated with anti-TLR-4 showed decreased expression of MyD88, but not TRIF, key mole-
cules in TLR-4 signaling. Phosphorylation of p38 and NF-κB p65 was re-
duced in arteries from anti-TLR-4-treated SHR versus IgG-treated SHR.
Hence, these results suggested that TLR-4/NFκB signaling pathway is a
key role in hypertension and vascular inﬂammatory process [122].
Other investigations have been conducted by other research groups
for identifying the molecular mechanisms mediated by TLR-4pathway
in inducing aortic VR and MD, which are pathological entities signiﬁ-
cantly associated with sporadic TAA, as above mentioned (see Fig. 5 B
and C). The group of Golzales-Ramos [123] pointed out that circulating
Hsp70 associatedwith increased aorta damage, regulates the proﬁbrotic
response of human aorta SMCs through increased TGF-1 expression,
evocated by TLR-4-mediated signaling pathway. In addition, Li and col-
leagues [124] reported the key role of TLR-4-mediated signaling path-
way in regulating the MMP-9 expression in HASMCs. Furthermore, a
recent study has demonstrated in apolipoprotein E-deﬁcient mice that
it is possible to limit the inﬂammatory process, blocking TLR-4/c-Jun N
terminal kinase signaling pathway with Rosiglitazone (a family of
drugs acting as agonists of the nuclear peroxisome proliferator-
activated receptors-PPARs) in the initiation stages of aortic aneurysm
development [125].
Based on these relevant ﬁndings, we ﬁrst assessed the role of ten ge-
netic variants (related to genes codifying molecules) of the TLR-4-
mediated signaling pathway in the susceptibility for sporadic TAA and
dissection [4,8,126]. Interestingly, we found that their combined geno-
typewas signiﬁcantly represented in sporadic TAA than controls. In sub-
sequent investigations, we also have shown that cases with this risk
genotype showed a higher systemic inﬂammatory mediator levels [8,
126], a signiﬁcant inﬂammatory/immune inﬁltrate [8,126],a typical
MD phenotype [127], a lower telomere length [128,129] and positive
correlations with histopatological abnormalities [126,127],hyperten-
sion, smoking, and aging [8,126–129]. Consequently, our ﬁndings
(even if prevalently of associated type) led us to suggest the key role
of TLR-4 pathway in the onset of this disease [4,8]. Moreover, they sup-
port actual growing evidence (as reported above), the suggestion and
consideration of the studies above described. Accordingly, it proposes
(see Fig. 5B and C) that the activation of TLR-4-mediated signaling path-
way, expressed both on EC and VSMC cells, could determine the activa-
tion or deregulation of ACE, NO,MMP, TGF-β pathways (associatedwith
endothelium dysfunction, extracellular matrix remodeling and chronic
inﬂammation) and as a consequence to induce the onset of VR and
MD, and sporadic TAA, as their complication. As a result, we postulated
(as above reported) a sporadic TAAmodel, whichwedeﬁned asmodel of
the signaling pathway from the double-face, given its features (see Fig. 4
of Ruvolo et al., 2014 study [8]; http://www.ncbi.nlm.nih.gov/pmc/
articles/PMC4120489/). We hope it could lead several researchers to
perform additional investigations useful to clarify the complexity of
this pathology. Certainly, future studies and additional efforts are neces-
sary, as well as a more complex combination of investigations based on
genetic, transcriptomic, proteomic,metabolomic, microbiomic and epige-
netic evaluations, since each individual is the result of the sophisticated
interplay between environmental factors and its genome, trascriptome,
proteome, metabolome, microbiome, epigenome, exposome (see Fig. 6).
This approachmight be very innovative, and it could provide valuable in-
sights about sporadic TAA pathophysiology, although it is very difﬁcult to
obtain human tissue aorta samples and appropriate controls. As an alter-
native solution (and more feasible), research cardiovascular community
proposes the use of appropriate animalmodels to study human aorta dis-
eases, i.e. sporadic TAA, providing themeans to test newpharmacological
interventions. However, there is a considerable debate in the ﬁeld of an-
eurysm's research on disadvantages and advantages associated with the
use of rat and mouse models, in which aneurysms can be generated in
several experimental settings [130,131]. Animal models have provided
useful information. However, a model, which replicates the chronic dis-
ease in humans, remains to be produced. Recently, largemammalmodels
have been used in the study of aortic aneurysms, including dog, pig,
Fig. 6. A suggested framework: integration of genome, transcriptome, proteome, metabolome, microbiome, epigenome, exoposome evaluations with computational investigations. Since
each individual is the result of the sophisticated interplay between environmental factors and its genome, trascriptome, proteome, metabolome, microbiome, epigenome, exposome, we
here suggest that it is necessary to perform a more complex combination of investigations based on genetic, transcriptomic, proteomic, metabolomic, microbiomic and epigenomic
evaluations, for obtaining interesting data in the study of sporadic TAA. In addition, computational investigations are also recommended, as well as collecting environmental and
biometric data, medical/scientiﬁc/health care records. Thus, we propose that the integration of all data, obtained in this large panel of assayses, and their elaboration might lead to the
development of appropriate agonists, antagonists, inhititors of TLR-4 signaling pathway, which might be used in a near future as personalized treatments for sporadic TAA (until now
inexistent), facilitating the management and outcome of this insidious deadly pathology.
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which the solutions are far less evident. Firstly, large animal models are
very expensive, and sometimes prohibitive. In addition, they also need a
very intensive work environment, requiring a large andmultidisciplinary
greater care. As a result, mouse models appear to be the best animal
model in aneurysm study so far, as they are relatively small, easy to han-
dle, andnot expensive. In addition, they can be geneticallymanipulated to
mimic human diseases, by generating “knockout” or “knock-in”models
and increasing their longevity in a rapidly evolving ﬁeld [130,131]. Thus,
this might facilitate the identiﬁcation of potential mechanisms and path-
ways related to aneurysms, such as sporadic TAA. Accordingly, they could
consent to investigate the relevance of TLR-4signaling pathway in aorta,
and precisely in both aorta health and diseases, sporadic TAA included
(as reported above). Thus, there is a great potential for animal studies to
improve our understanding of sporadic TAA pathophysiology, with the
aim of improving current patient management strategies.
6. Therapeutic role of TLR-4 pathway: from experimental data to de-
velopment of innovative therapies
Overall, the data, above stressed, highlighted the relevant role of the
TLR-4 signaling pathway in aortic diseases, i.e. sporadic TAA, although
unclear responses and a number of gaps have to be resolved. However,
they encourage the approach of translational medicine (TM), an emerg-
ing and multidisciplinary area and a new tool for improving human
health by reducing the incidence,morbidity andmortality of the disease
[132–135]. Translational research turns scientiﬁc discoveries found in
the laboratory inways to prevent diagnosis or treat diseases (i.e. person-
alized therapies). In the speciﬁc case of aneurysms, translational scien-
tists are primarily focusing on their interest on inﬁlling knowledge of
related TAA phenotypes (i.e. hypertension, VR, MD and its complica-
tions, such as sporadic TAA), obtained from in vitro and experimental
animal models, with pathways of disease indentiﬁed in humans, such
as the TLR-4-pathway. The identiﬁcation of susceptibility genes, associ-
ated with these pathways of disease and which allows patients to
achieve personalized treatments, is their subsequent purposes.In regards to TLR-4 pathway, biotechnology companies are develop-
ing various drugs (i.e. agonists or antagonists), ranging from proteins
tometal ions, such as pharmacological treatments tomodulate its activa-
tion under atherosclerosis, ischemic heart disease, heart failure, ischemic
reperfusion injury, and aneurysm [136,137]. A considerable number of
them are listed in Table 5, together with their effects [136,137]. With re-
gard to the latter, some have been reported in the studies described [115,
120–125] in the previous paragraph. Their action has shown that both
the TLR-4 activation and inhibitionmay have beneﬁcial effects in various
conditions, reducing tissue immune inﬂammatory responses [115,
120–125,136,and 137]. This result can be explained with the diverse in-
teraction of the TLR-4 pathway with different pathways, expressed dif-
ferently in various types of experimental models used, as mentioned
above. However, the TLR-4 modulators and their biological effects
seem to be dependent on other factors, includingﬁrstly the timing of ad-
ministration during the various stages of disease onset and progression,
as well as the age and genetic background of animal models used at
the time of experimentation. In this regards, we have highlighted in a re-
cent review [11], that there are age-related defects in TLR-4 function and
expression, as reported in human studies, although these studies have
did not led conclusive data, being limited by the heterogeneity of epide-
miological and laboratory methods. This could also be valid for the ani-
mals used as a model of study. Furthermore, as mentioned above, the
TLR-4 function and expression are modulated not only by genetic vari-
ants and haplotypes [11,85,86] but also by environmental factors (such
as diet [138–141], mite allergens [142], air pollution [143]), and their
cross-interaction with microbiota [141], which may remain in a healthy
state or show alterations (i.e. dysbiosis and consequent endotoxemia as-
sociated with age or obesity) [144,145]and consequent epigenetic
changes [146,147]. Thus,many limitations and concerns emerge. In addi-
tion, another relevant limitation derives from the type of experimenta-
tion. Precisely, agonists and antagonists have been mainly analyzed in
cell cultures and animal models [136,137]. Thus, only preclinical studies
exist until now, and no human trials have been performed. As a conse-
quence, the encouraging data obtainedmaynot be conﬁrmed in humans.
In fact, there are many concerns in this ﬁeld. The ﬁrst concern comes
Table 5
Pharmacological Agonists and Antagonists and natural small molecules modulating TLR-4 signaling pathway [115,120–125,136,137].
Molecules Action Diseases Preclinical
studies
BCG TLR-4 agonist Cardiac
hypertrophy
Mouse
Eritoran TLR-4 antagonist Cardiac
ischemia;
Cardiac
Hyperthrophy
Renal injury
Rat;
Mouse
Valsartan TLR-4 inhibitor Cardiac
ischemia
Rat
Atorvastatin TLR-4 inhibitor Cardiac
ischemia
In vitro
Losartan TLR-4 inhibitor Cardiac Failure Mouse
Fluvastatin TLR-4 inhibitor Cardiac Failure In vitro
Cinnamic acid TLR-4 inhibitor Myocarditis Mouse
Geldanamycin TLR-4 inhibitor Myocardial
inﬂammation
Mouse
Baicalin TLR-4 inhibitor Brain ischemia Rat
Oxymatrine TLR-4 inhibitor Brain ischemia Rat
Progesterone TLR-4 inhibitor Brain ischemia Rat
Gynkgobiloba TLR-4 inhibitor Brain ischemia Rat
Picroside 2 TLR4 inhibitor Brain ischemia Rat
Oestrogen TLR4 inhibitor Lung/ischemia
reperfusion
Mouse
Dexmedetomidine TLR4 inhibitor Renal ischemia Mouse
Melatonin TLR4 inhibitor Liver/ischemia
reperfusion
Rat
Surforaphane
Cinnamaldehyde
Curcumin
TLR4 inhibitors, by blocking oligomerization of the receptor Inﬂammatory
diseases
Rat;
Mouse,
in vitro
Epigallocatechin gallate (EGCG), resveratrol and certain ﬂavonoids
such as lutelolin, quercetin, chrysin, and eriodictyol
TLR4 inhibitors: have the ability to decrease kinase activity of TBK1
activating IRF
Inﬂammatory
diseases
Rat;
Mouse,
in vitro
Xanthohumol (XN) TLR4 inhibitor: XN is anti-inﬂammatory natural product from hops and beer,
it can block the TLR4 signaling by binding to MD-2 directly
Inﬂammatory
diseases
Rat;
Mouse,
in vitro
Ligustrazine, a natural alkaloid compound TLR4 inhibitor Inﬂammatory
diseases
Rat;
Mouse,
in vitro
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large number of researchers claim that only a subset of them could prob-
ably activate or inhibit directly the TLR-4 pathway. Their structural diver-
sity is enormous, and this suggests promiscuity in their TLR-4 binding
capacity, without speciﬁcity of action, and rather a pleiotropic effect on
different receptors. In this regard, Mancek-Keber and Jerala [148] have
proposed three postulates to distinguish direct agonists from indirect ac-
tivators: (1) the agonist requires the TLR-4/MD-2 receptor complex;
(2) either synthetically or in situ, they must activate the receptor com-
plex in order to eliminate artefacts fromother agonists; and (3) a speciﬁc
molecular interaction between the agonist and TLR-4/MD-2 must be
identiﬁed. Furthermore, in 2016 the group of Martin-Santamaria [149,
150] proposed to use computational approaches [149] and big databases
[150] for the identiﬁcation of all atomic details in the TLR-4 receptor
structure itself and the ligand-receptor interactions of different modula-
tors to develop novel agonists and antagonists with promising biomedi-
cal applications, to reduce toxic effects, and improve drug-like
properties, ﬁne-tuning of relative potency of agonists and antagonists,
binding capacity and speciﬁcity.
Similar considerationsmay also be valid for small natural molecules,
such as curcumin, cinnamaldehyde and sulforaphane, which have been
reported to mediate the anti-TLR4 dimerization effects, as well as for
resveratrol and some ﬂavonoids (such as EGCG, lutelolin, quercetin,
chrysin, and eriodictyol), that have been reported to inhibit TBK1 kinase
activity (a downstream TLR4 signaling kinase), resulting in a decreased
IRF3 activation, a TLR4 signaling adaptator, and target gene expression
[101–104,150] (see Table 5).
On the one hand, these observations support the idea that these
molecules can ﬁnd clinical implementations in the near future tofacilitate management and to develop treatments so far inexistent for
aortic aneurysms, such as sporadic TAA. On the other hand, they suggest
that the solution can be in putting together the investigations, sug-
gested in the preceding paragraph, with the evaluations of TLR-4 mod-
ulators described above to facilitate the development of personalized
treatments for aortic diseases, i.e. sporadic TAA (see Fig. 6). Probably,
looking with new eyes the investigations and the results obtained
might be of help in order to make new discoveries, although the way
of research to practice is still long and difﬁcult, as suggested in our stud-
ies [4,8].
7. Conclusions and future perspectives
The human aorta is the main vessel, which carries blood pumped
from the left ventricle to the systemic circulation. Thus, aorta has a de-
cisive role in contributing to the health of all tissues, organs and systems
of the human body, providing oxygen and nutrients. A very sophisticat-
ed control regulates its activity and contributes tomaintaining a ﬁneho-
meostasis. This regulation (similarly to that regulating the entire
cardiovascular system) is dominated by the central nervous system
(CNS) [151], the knowledge of which in the past 20 years has signiﬁ-
cantly evolved. This control is also supported, or rather induced by auto-
nomic nervous system (ANS) [152], which completes the primary ring
of homeostasis body's control along with the immune and endocrine
systems. These latter, through molecular pathways of innate signaling
(likely TLR-4 signaling pathway) and hormones (i.e. reproductive hor-
mones), which were not classically viewed as CV (aorta included) sig-
naling pathways, mediate both ANS and CNS target effects in
traditional and not traditional manner [152]. In fact, they also act via
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which have been shown to have profound effects on the central control
of blood pressure and activity of stress and stretch signalingpathways of
aortic EC and VSCM cells [153,154]. In addition, recent investigations
carried out in particular on mice have shown that the activation of me-
chanical and strain stress (i.e. ACE, TGF-β) induces inﬂammation and
degeneration, and it increases hypertension, providing insight into for-
mation and progression of aorta diseases, including sporadic TAA and
dissection (see Figs. 2 and 5 B and C) [154,155]. In turn, chronic inﬂam-
mation, such as chronic signal, vascular aging and CVD onset, such as
sporadic TAA, has been shown (see Fig. 5 B and C) [34,36,and 37,156].
Overall, these observations suggest that inﬂammation is now recog-
nized as the basic mechanism of aging of the cardiovascular system, in-
cluding the related diseases, as sporadic TAAs [156,157]. On the other
hand, a longitudinal study performed in 2016 in a very wide range of
age from 45 to 115 years (1554 enrolled individuals), including unprec-
edented large numbers of extremely old, suggested that inﬂammation is
an important aging driver and its reduced levels could be an optimal
biomarker for a successful aging with respect to telomere length
[158]. Thus, future pharmacological intervention on inﬂammation may
be amenable [158]. Our data gathered for over 10 years in Sicilian cen-
tenarians are in agreement with these results [79]. Based on results ob-
tained, we, indeed, suggest that longevity is the result of an optimal
performance of the immune system and an over-expression of anti-
inﬂammatory sequence variants of immune/inﬂammatory genes. We
mutually demonstrate that age-related diseases are evoked by chronic
inﬂammation and by an over-representation of pro-inﬂammatory
gene variants of immune/inﬂammatory genes [79]. Furthermore, we
underline that an intricate inﬂammatory network is involved in the
complex pathophysiology of age-related diseases, where the TLR-4 sig-
naling pathway acts as hub [9,11]. Likewise, here, we point the key role
of the TLR-4 signaling pathway in aorta health and diseases, and partic-
ularly in sporadic TAA, highlighting a onset model [4,8]. In addition, we
point out that its versatility of action and function and its consequent
pleiotropic effects are the result of a complex cross-talk with other sig-
naling pathways, such as the Notch pathway, as we have highlighted in
a recent review [89]. Certainly, further investigations to validate and
conﬁrm the role of the TLR-4 signaling pathway in sporadic TAA, are
needed. However, it should be noted that this report may lead several
researchers to perform additional studies to clear the complex puzzle
of this pathology. Future studies and additional efforts are imperative.
Here, we propose that a combination of analyses (see Fig. 6) can be
helpful. The results obtained could favor the development of personal-
ized treatments for sporadic TAA, until now inexistent. In this context,
investigations that clarify the effects of environmental triggers, such as
diet, allergens, air pollution, in the pathophysiology of aorta aging and
diseases (i.e. sporadic TAA) through activation of TLR-4 pathway, in-
cluding the intriguing link between the intestinal microbiota and CVD
mediated by the TLR4-pathway, might be helpful (see Fig. 6).
To achieve this goal, ourmessage is “Wemust not give up in the face of
many difﬁculties, that we face in performing our research… but above all
we must not forget that the ultimate goal of our experiments should be
the good for the man and not the love for the success… motivated exclu-
sively by this… the perseverance, collaboration and honest activity, togeth-
er with the necessary funding, will allow us to convert assumptions into
certainties”.
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